ArticleEMBO molecular medicine2022

A novel platform for attenuating immune hyperactivity using EXO-CD24 in COVID-19 and beyond.

Shiran Shapira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.